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To the Editor: Contrary to early 
expectations, the co-occurrence of lep-
rosy and HIV has not increased glob-
ally (1). However, most of the larger 
studies on the subject were conducted 
in the early to mid-1990s in African 
countries, and the research designs 
had limited power to describe the true 
effects of co-infection (1). Moreover, 
the introduction of highly active an-
tiretroviral therapy (HAART), which 
has been used routinely in Brazil since 
1996, altered the clinical evolution of 
HIV infection (2) and led to increas-
ing reports of immune restoration 
inﬂ   ammatory syndrome (IRIS) as-
sociated with leprosy (3,4). Although 
some researchers have argued that 
this association may not affect public 
health (2), its true importance remains 
to be clariﬁ  ed. Finally, leprosy has a 
wide range of clinical manifestations, 
which sometimes imposes a clinical 
challenge and may lead to misdiag-
nosis (5). Together, these factors may 
have helped mask the true scenario of 
leprosy and HIV co-infection, particu-
larly in areas where these conditions 
are highly endemic. In this context, 
case reports from referral centers 
that reﬂ  ect the broad clinical aspects 
of leprosy and HIV co-occurrence 
are important to increase clinicians’ 
awareness of both diseases.
We report 3 HIV-positive/AIDS 
patients who showed different clinical 
manifestations of leprosy; their condi-
tions were diagnosed before and after 
HAART initiation. All patients lived 
in Manaus, the capital of the state of 
Amazonas in Brazil, an area where 
both leprosy and HIV infection are 
endemic. The 3 patients represent a 
sample from our 11-year experience 
with 21 patients with leprosy and HIV 
co-infection. 
Patient 1 was a 29-year-old 
woman whose HIV-1 infection was 
diagnosed in May 2002 at antenatal 
examination. Her CD4 cell count in 
2002 was 513 cells/μL. In Novem-
ber 2007, she sought treatment at 
the Institute of Tropical Medicine of 
Amazonas with a 3-month history of a 
single erythematous plaque on her left 
arm, which was clinically diagnosed 
as borderline tuberculoid (BT) lep-
rosy. The patient’s sensitivity to pain 
was decreased. There was no nerve 
enlargement. Histopathologic exami-
nation conﬁ  rmed the diagnosis, show-
ing a granulomatous dermatitis with 
no acid-fast bacilli on Wade stain. At 
this time, her CD4 cell count was 342 
cells/μL. HAART and multidrug ther-
apy (MDT) for paucibacillary leprosy 
were initiated. The leprosy resolved, 
and the lesion disappeared within 2 
months of therapy.
Patient 2 was a 22-year-old man 
who had neurocryptococcosis and 
HIV infection diagnosed in September 
2007. At that time, he exhibited dis-
seminated, inﬁ   ltrated lesions on the 
trunk and upper and lower limbs. Bor-
derline lepromatous (BL) leprosy was 
clinically diagnosed. Skin biopsy con-
ﬁ  rmed the diagnosis; the biopsy speci-
men showed a granulomatous dermati-
tis, foamy cells, and multiple acid-fast 
bacilli. His CD4 cell count was 6 cells/
μL. HAART and MDT for multibacil-
lary leprosy were prescribed. In Feb-
ruary 2008, the patient was readmitted 
to the Institute of Tropical Medicine 
of Amazonas and died of nonspeciﬁ  ed 
bacterial pneumonia and sepsis.
Patient 3 was a 23-year-old wom-
an who had HIV-1 infection (CD4 cell 
count 435 cells/μL) diagnosed in No-
vember 2006 at antenatal examination. 
HAART was begun 3 months later. In 
August 2008, she sought treatment 
with a 3-month history of a single 
patch on the left leg with erythematous 
papules on its border (Figure). There 
was decreased pain sensitivity in the 
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lesion and no nerve enlargement. At 
that time, her CD4 cell count was 372 
cells/μL. Histopathologic examination 
showed tuberculoid granulomas con-
sisting of lymphocytes and epithelioid 
cells. Wade staining showed no acid-
fast bacilli. Histopathologic ﬁ  ndings 
led to a diagnosis of BT leprosy. MDT 
for paucibacillary leprosy was prompt-
ly started, and HAART was continued. 
When she was last seen, in December 
2008, the skin lesion had disappeared 
and she was still receiving MDT.
The reliability of the cardinal 
signs of leprosy (hypopigmented or 
reddish patches with deﬁ  nite  loss 
of sensation, thickened peripheral 
nerves, and positive skin smears or 
biopsy material) has been widely ac-
cepted (5). However, in some difﬁ  cult 
cases, the deﬁ   nitive diagnosis relies 
solely on the histopathologic exami-
nation, which often depends on the ex-
perience of the  pathologists working 
in referral centers. According to most 
pre-HAART studies, the clinical spec-
trum of leprosy seems to be preserved 
in HIV-positive and AIDS patients (1). 
This is in agreement with the course of 
disease in patient 1 (a typical BT lesion 
before initiating HAART) and patient 
2 (a typical multibacillary leprosy in 
a full-blown AIDS background). For 
patient 3, a distinct outcome was ob-
served: the appearance of an atypical 
BT lesion during HAART. Recently, 
we reported 3 cases of IRIS associ-
ated with leprosy in which BL leprosy 
shifted unexpectedly to BT leprosy 
(4,6). Host genetic make-up and un-
known consequences of HIV-infection 
over speciﬁ  c leprosy immune mecha-
nism may be implicated in these un-
usual outcomes. Further prospective 
studies should be performed to eluci-
date these ﬁ  ndings.
Although previous studies have 
shown that HIV infection is not a risk 
factor for leprosy (1), clinicians should 
be aware of this potential co-infection, 
which may mimic different skin dis-
eases. Moreover, reports of leprosy 
after HAART initiation have been de-
scribed from countries where leprosy 
is not endemic (7). Precise diagnosis 
and prompt treatment of leprosy in co-
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Figure. Skin lesion of patient 3, a solitary patch on the left leg with erythematous papules 
on the border.